Sodium glucose cotransporter-2 (SGLT2) inhibitors or gliflozins improve HF-related outcomes and this beneficial influence occurs irrespective of the presence or absence of type 2 diabetes [9,104,105,106,107]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.